Search results
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 13 hours agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Is It Too Late to Buy Novavax Stock? | The Motley Fool
The Motley Fool· 7 days agoNovavax (NVAX -4.32%) stock is suddenly a buy again this year, with its stock price more than...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News· 6 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 7 days agoOn June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held...
FDA asks COVID vaccine makers to target KP.2 strain, if feasible, for next shot
Reuters via Yahoo News· 6 days agoThe Food and Drug Administration's change in recommendation, in an update dated Thursday, comes even...
FDA Tells Vaccine Makers to Target New COVID Variant for Fall | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 7 days agoCOVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News via Yahoo News· 6 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
Is It Too Late to Buy Novavax Stock?
Motley Fool via Yahoo Finance· 7 days agoNovavax. Just be aware that the bullishness only goes so far. The consensus analyst price target on the healthcare stock is $17.50, which is only about...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 13 hours agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Is It Too Late to Buy Novavax Stock?
The Motley Fool via AOL· 7 days agoNovavax. Just be aware that the bullishness only goes so far. The consensus analyst price target on the healthcare stock is $17.50, which is only about 9% higher than the ...